Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX
$3.86
-$0.025-0.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.68M | 10.92M | 9.76M | 9.40M | 8.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.43M | 27.00M | 31.50M | 31.85M | 31.00M |
| Operating Income | -27.43M | -27.00M | -31.50M | -31.85M | -31.00M |
| Income Before Tax | -26.36M | -25.74M | -28.78M | -27.69M | -31.13M |
| Income Tax Expenses | -400.00 | 1.80K | 36.40K | 36.40K | 41.40K |
| Earnings from Continuing Operations | -26.35 | -25.74 | -28.82 | -27.72 | -31.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 132.80K | 242.00K | 599.00K | 725.70K | 798.40K |
| Net Income | -26.22M | -25.50M | -28.22M | -27.00M | -30.37M |
| EBIT | -27.43M | -27.00M | -31.50M | -31.85M | -31.00M |
| EBITDA | -34.70M | -34.27M | -31.40M | -31.76M | -30.89M |
| EPS Basic | -0.98 | -0.98 | -0.92 | -0.94 | -1.20 |
| Normalized Basic EPS | -0.46 | -0.47 | -0.57 | -0.58 | -0.73 |
| EPS Diluted | -0.98 | -0.99 | -0.92 | -0.94 | -1.20 |
| Normalized Diluted EPS | -0.46 | -0.47 | -0.57 | -0.58 | -0.73 |
| Average Basic Shares Outstanding | 142.57M | 135.70M | 127.36M | 117.27M | 103.65M |
| Average Diluted Shares Outstanding | 142.57M | 135.70M | 127.36M | 117.27M | 103.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |